Taipei, Feb. 15 (CNA) The Taiwanese vaccine maker, Medigen Vaccine Biologics Corp., said Tuesday that a World Health Organization-led (WHO) clinical trial of its COVID-19 vaccine could be unblinded in March at the earliest.
The locally developed Medigen COVID-19 vaccine has successfully completed a phase 3 clinical trial in Paraguay and received emergency use authorization (EUA) from the South American nation.
The Taiwanese vaccine manufactured by Medigen Vaccine Biologics Corp (高端疫苗) was hailed by Taiwanese experts as an important milestone for domestically produced vaccines.
Medigen’s vaccine has been gaining recognition from international institutions. It has been included in the WHO’s Solidarity Trial Vaccines program and received a US$2.3 million grant from the Coalition for Epidemic Preparedness Innovations to conduct a mix-and-match trial.
A double-blind, randomized study was used in the clinical trial in Paraguay to compare Medigen’s
GLOBAL APPROVAL: Medigen is now waiting for the results of the WHO’s clinical trial evaluating the effectiveness of vaccines from around the worldBy Chiu Chih-jou and Liu Tzu-hsuan / Staff reporter, with staff writer